OBJECTIVES: This study sought to determine if simvastatin impairs exercise training adaptations. BACKGROUND: Statins are commonly prescribed in combination with therapeutic lifestyle changes, including exercise, to reduce cardiovascular disease risk in patients with metabolic syndrome. Statin use has been linked to skeletal muscle myopathy and impaired mitochondrial function, but it is unclear whether statin use alters adaptations to exercise training. METHODS: This study examined the effects of simvastatin on changes in cardiorespiratory fitness and skeletal muscle mitochondrial content in response to aerobic exercise training. Sedentary overweight or obese adults with at least 2 metabolic syndrome risk factors (defined according to National Cholesterol Education Panel Adult Treatment Panel III criteria) were randomized to 12 weeks of aerobic exercise training or to exercise in combination with simvastatin (40 mg/day). The primary outcomes were cardiorespiratory fitness and skeletal muscle (vastus lateralis) mitochondrial content (citrate synthase enzyme activity). RESULTS:Thirty-seven participants (exercise plus statins: n = 18; exercise only: n = 19) completed the study. Cardiorespiratory fitness increased by 10% (p < 0.05) in response to exercise training alone, but was blunted by the addition of simvastatin resulting in only a 1.5% increase (p < 0.005 for group by time interaction). Similarly, skeletal muscle citrate synthase activity increased by 13% in the exercise-only group (p < 0.05), but decreased by 4.5% in the simvastatin-plus-exercise group (p < 0.05 for group-by-time interaction). CONCLUSIONS:Simvastatin attenuates increases in cardiorespiratory fitness and skeletal muscle mitochondrial content when combined with exercise training in overweight or obese patients at risk of the metabolic syndrome. (Exercise, Statins, and the Metabolic Syndrome; NCT01700530).
RCT Entities:
OBJECTIVES: This study sought to determine if simvastatin impairs exercise training adaptations. BACKGROUND: Statins are commonly prescribed in combination with therapeutic lifestyle changes, including exercise, to reduce cardiovascular disease risk in patients with metabolic syndrome. Statin use has been linked to skeletal muscle myopathy and impaired mitochondrial function, but it is unclear whether statin use alters adaptations to exercise training. METHODS: This study examined the effects of simvastatin on changes in cardiorespiratory fitness and skeletal muscle mitochondrial content in response to aerobic exercise training. Sedentary overweight or obese adults with at least 2 metabolic syndrome risk factors (defined according to National Cholesterol Education Panel Adult Treatment Panel III criteria) were randomized to 12 weeks of aerobic exercise training or to exercise in combination with simvastatin (40 mg/day). The primary outcomes were cardiorespiratory fitness and skeletal muscle (vastus lateralis) mitochondrial content (citrate synthase enzyme activity). RESULTS: Thirty-seven participants (exercise plus statins: n = 18; exercise only: n = 19) completed the study. Cardiorespiratory fitness increased by 10% (p < 0.05) in response to exercise training alone, but was blunted by the addition of simvastatin resulting in only a 1.5% increase (p < 0.005 for group by time interaction). Similarly, skeletal muscle citrate synthase activity increased by 13% in the exercise-only group (p < 0.05), but decreased by 4.5% in the simvastatin-plus-exercise group (p < 0.05 for group-by-time interaction). CONCLUSIONS:Simvastatin attenuates increases in cardiorespiratory fitness and skeletal muscle mitochondrial content when combined with exercise training in overweight or obesepatients at risk of the metabolic syndrome. (Exercise, Statins, and the Metabolic Syndrome; NCT01700530).
Authors: Ryan D Sheldon; Bruno T Roseguini; John P Thyfault; Brett D Crist; M H Laughlin; Sean C Newcomer Journal: J Appl Physiol (1985) Date: 2012-03-22
Authors: B A Schick; R Laaksonen; J J Frohlich; H Päivä; T Lehtimäki; K H Humphries; H C F Côté Journal: Clin Pharmacol Ther Date: 2007-02-28 Impact factor: 6.875
Authors: P Sirvent; O Fabre; S Bordenave; D Hillaire-Buys; E Raynaud De Mauverger; A Lacampagne; J Mercier Journal: Toxicol Appl Pharmacol Date: 2012-01-17 Impact factor: 4.219
Authors: R Scott Rector; Grace M Uptergrove; E Matthew Morris; Sarah J Borengasser; M Harold Laughlin; Frank W Booth; John P Thyfault; Jamal A Ibdah Journal: Am J Physiol Gastrointest Liver Physiol Date: 2011-02-24 Impact factor: 4.052
Authors: R Scott Rector; Grace M Uptergrove; Sarah J Borengasser; Catherine R Mikus; E Matthew Morris; Scott P Naples; Matthew J Laye; M Harold Laughlin; Frank W Booth; Jamal A Ibdah; John P Thyfault Journal: Am J Physiol Endocrinol Metab Date: 2010-03-16 Impact factor: 4.310
Authors: Donald B Hunninghake; Christie M Ballantyne; Darbie L Maccubbin; Arvind K Shah; Barry Gumbiner; Yale B Mitchel Journal: Clin Ther Date: 2003-06 Impact factor: 3.393
Authors: Steen Larsen; Joachim Nielsen; Christina Neigaard Hansen; Lars Bo Nielsen; Flemming Wibrand; Nis Stride; Henrik Daa Schroder; Robert Boushel; Jørn Wulff Helge; Flemming Dela; Martin Hey-Mogensen Journal: J Physiol Date: 2012-05-14 Impact factor: 5.182
Authors: Jacob P Kelly; Allison Dunning; Phillip J Schulte; Mona Fiuzat; Eric S Leifer; Jerome L Fleg; Lawton S Cooper; Steven J Keteyian; Dalane W Kitzman; Ileana L Pina; William E Kraus; David J Whellan; Christopher M O'Connor; Robert J Mentz Journal: JACC Heart Fail Date: 2016-07-06 Impact factor: 12.035
Authors: Mridula Ramesh; Juliane C Campos; Pamela Lee; Yang Song; Genaro Hernandez; Jon Sin; Kyle C Tucker; Hannaneh Saadaeijahromi; Michael Gurney; Julio C B Ferreira; Allen M Andres Journal: FASEB J Date: 2019-08-23 Impact factor: 5.191
Authors: Lauren K Park; Elizabeth J Parks; Ryan J Pettit-Mee; Makenzie L Woodford; Thaysa Ghiarone; James A Smith; Allan R K Sales; Luis A Martinez-Lemus; Camila Manrique-Acevedo; Jaume Padilla Journal: J Appl Physiol (1985) Date: 2020-07-02
Authors: Benjamin J Ryan; Michael W Schleh; Cheehoon Ahn; Alison C Ludzki; Jenna B Gillen; Pallavi Varshney; Douglas W Van Pelt; Lisa M Pitchford; Thomas L Chenevert; Rachel A Gioscia-Ryan; Suzette M Howton; Thomas Rode; Scott L Hummel; Charles F Burant; Jonathan P Little; Jeffrey F Horowitz Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958